🚀 VC round data is live in beta, check it out!
Profusa Valuation Multiples
Discover revenue and EBITDA valuation multiples for Profusa and similar public comparables like Nuwellis, Monivent, PExA, SpectraCure and more.
Profusa Overview
About Profusa
Profusa Inc is a clinical-stage digital health and medical technology company focused on developing biosensing solutions to improve health outcomes for patients with a variety of different diseases and conditions. The Company’s technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company’s first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.
Founded
2021
HQ
Employees
N/A
Website
Sectors
Financials (FY)
EV
$16M
Profusa Financials
Profusa reported last fiscal year revenue of — and negative EBITDA of ($33M).
In the same fiscal year, Profusa generated ($33M) in EBITDA losses and had net loss of ($36M).
Profusa P&L
In the most recent fiscal year, Profusa reported revenue of — and EBITDA of ($33M).
Profusa expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($33M) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($36M) | XXX | XXX | XXX |
| Net Debt | — | — | $13M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Profusa Stock Performance
Profusa has current market cap of $3M, and enterprise value of $16M.
Market Cap Evolution
Profusa's stock price is $0.68.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $16M | $3M | 0.0% | XXX | XXX | XXX | $-8.12 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialProfusa Valuation Multiples
Profusa trades at (0.5x) EV/EBITDA.
Profusa Financial Valuation Multiples
As of April 20, 2026, Profusa has market cap of $3M and EV of $16M.
Equity research analysts estimate Profusa's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Profusa has a P/E ratio of (0.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3M | XXX | $3M | XXX | XXX | XXX |
| EV (current) | $16M | XXX | $16M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.5x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (0.6x) | XXX | XXX | XXX |
| P/E | — | XXX | (0.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (1.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Profusa Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Profusa Margins & Growth Rates
Profusa's revenue in the last fiscal year grew by —.
Profusa Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | 593% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Profusa Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Profusa | XXX | XXX | XXX | XXX | XXX | XXX |
| Nuwellis | XXX | XXX | XXX | XXX | XXX | XXX |
| Monivent | XXX | XXX | XXX | XXX | XXX | XXX |
| PExA | XXX | XXX | XXX | XXX | XXX | XXX |
| SpectraCure | XXX | XXX | XXX | XXX | XXX | XXX |
| Massmedica | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Profusa M&A Activity
Profusa acquired XXX companies to date.
Last acquisition by Profusa was on XXXXXXXX, XXXXX. Profusa acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Profusa
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialProfusa Investment Activity
Profusa invested in XXX companies to date.
Profusa made its latest investment on XXXXXXXX, XXXXX. Profusa invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Profusa
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Profusa
| When was Profusa founded? | Profusa was founded in 2021. |
| Where is Profusa headquartered? | Profusa is headquartered in United States. |
| Who is the CEO of Profusa? | Profusa's CEO is Ben C. Hwang. |
| Is Profusa publicly listed? | Yes, Profusa is a public company listed on Nasdaq. |
| What is the stock symbol of Profusa? | Profusa trades under PFSA ticker. |
| When did Profusa go public? | Profusa went public in 2025. |
| Who are competitors of Profusa? | Profusa main competitors are Nuwellis, Monivent, PExA, SpectraCure. |
| What is the current market cap of Profusa? | Profusa's current market cap is $3M. |
| Is Profusa profitable? | No, Profusa is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.